Pfizer (PFE.US) Tukysa approved in the U.S. for first-line breast cancer treatment

Zhito Finance APP has learned that Pfizer (PFE.US) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor Tukysa (tucatinib) as part of a combination therapy regimen for first-line maintenance treatment of a certain type of breast cancer.